Summary:
We are conducting a Double-Blind, Placebo Controlled, Crossover, Two-Attack, Out-patient, early intervention evaluation of subjects who have migraine headaches and who recently (within the past year) discontinued use of Eletriptan (Relpax) due to non-response or intolerance.
Qualified Participants Must:
• Be 18 to 65 years old
•
Suffer with migraine headaches
•
Be good general health
Qualified Participants May Receive:
Participants in the study will be asked to take an investigational drug to treat 2 migraine attacks. Participants will receive all study related care. Compensation is available.